Novo Nordisk to present real-world and clinical data at EASD 2026
Novo Nordisk says it will present new data from its cardiometabolic pipeline and portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026) in Milan, Italy, from 28 September to 2 October 2026, including real-world and clinical data for its Wegovy® pill and cardiometabolic pipeline progress, plus next-generation amylin treatments.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.